Stock AnalizuniQure N.V. QURE
Biotechnology: Pharmaceutical Preparations · IPO 2014 · data as of November 13, 2026
uniQure N.V. (QURE) is a healthcare company listed in the US with a market value of about $1.7B. In the twelve months to September 30, 2026 it had revenue of $20M and net income of -$233M, a net margin of -1154.8%.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is future growth (2/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of -16% a year, a 5-year average ROIC of -57%.
Score: 0.6 / 5
Checks passed
- Profit margin improving
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $20M | $16M | $27M | $16M | $106M | $524M | $38M | $7M | $11M | $13M | $25M |
| Net income | -$233M | -$199M | -$240M | -$308M | -$127M | $330M | -$125M | -$124M | -$83M | -$79M | -$73M |
| Free cash flow | -$193M | -$178M | -$186M | -$153M | -$163M | $271M | -$142M | -$104M | -$78M | -$69M | -$87M |
| EPS (diluted) | $-3.51 | $-3.46 | $-4.92 | $-6.47 | $-2.71 | $7.04 | $-2.81 | $-3.11 | $-2340.00 | $-2940.00 | $-2930.00 |
| Net margin | -1154.8% | -1236.0% | -883.4% | -1947.1% | -119.1% | 62.9% | -333.3% | -1705.8% | -738.2% | -604.7% | -292.4% |
| ROIC | — | -51.5% | -196.7% | -57.0% | -21.4% | 40.2% | -34.4% | -23.5% | -30.6% | -62.8% | -67.8% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 11 analysts is $59.63, 150% above the current price; targets range from $27.60 to $93.66; the consensus rating is “Strong buy”; expected EPS is $-3.33 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does uniQure pay a dividend?
Not currently.
Is uniQure a good stock to buy?
We do not give buy or sell advice. uniQure scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.